1st Quarter - Report — PURDUE PHARMA, LP for PURDUE PHARMA LP (2012)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

PURDUE PHARMA, LP

Client

PURDUE PHARMA LP

Income

—

Expenses

$3,000,000

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
1st Quarter - Report (this page)	Apr 19, 2012	$3,000,000	Replaced
1st Quarter - Amendment	Apr 24, 2012	$300,000	Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Anti- counterfeiting legislation concerning drugs (pedigree) Disposal of Drugs Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation RiskEvaluation and MitigationStrategies for controlled substances HR 4956 - Stop Oxy Abuse Act

Lobbyist	Covered position, as disclosed
BURT E ROSEN	—

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 4956 (112th)

Copyright/Patent/Trademark CPT

Lobbyist	Covered position, as disclosed
BURT E ROSEN	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 4956 (112th)

Health Issues HCR

Lobbyist	Covered position, as disclosed
BURT E ROSEN	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 4956 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.